Spots Global Cancer Trial Database for First in Human Study of TORL-3-600 in Participants With Advanced Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First in Human Study of TORL-3-600 in Participants With Advanced Cancer
Official Title: A Phase 1, First in Human, Dose-Escalation Study of TORL-3-600 in Participants With Advanced Cancer
Study ID: NCT05948826
Interventions
Study Description
Brief Summary: This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
Washington University School of Medicine-Siteman Cancer Center, Saint Louis, Missouri, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
McGill University Health Centre, Montréal, Quebec, Canada
Contact Details
Name: Stephen Letrent, PharmD, PhD
Affiliation: TORL Biotherapeutics, LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
